organization · Reporting owner

Versant Side Fund IV, L.P.

Disclosed activity across 6 companies

Tapewire entity: 88367
SEC CIK: 0001456591

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	10% owner	April 20, 2018	April 24, 2018
Tempest Therapeutics, Inc.TPST · Entity 7734	10% owner	August 08, 2024	August 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date April 20, 2018 · Filed April 24, 2018

Jointly reported with Versant Venture Capital IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Venture Capital V (Canada), LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee footnote	2,238,979	Reported balance After 2018-04-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-04-20 · Other · Disposed 497,053 · Balance 2,238,979 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	13,277	Reported balance After 2018-04-20 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-04-20 · Other · Disposed 2,947 · Balance 13,277 F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	92,918	Reported balance After 2018-04-20 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-04-20 · Other · Acquired 92,918 · Balance 92,918 F5: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6: The shares are held by VV IV.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2018-04-20 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-04-20 · Other · Disposed 92,918 · Balance 0 F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6: The shares are held by VV IV.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	1,539,576	Reported balance After 2018-04-23 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2018-04-23 · Sale · Disposed 89,628 · Balance 1,539,576 F8: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F10: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	45,171	Reported balance After 2018-04-23 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2018-04-23 · Sale · Disposed 2,630 · Balance 45,171 F11: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F12: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	50,072	Reported balance After 2018-04-23 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2018-04-23 · Sale · Disposed 2,915 · Balance 50,072 F13: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F14: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	117,173	Reported balance After 2018-04-23 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2018-04-23 · Sale · Disposed 6,821 · Balance 117,173 F15: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F16: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.

F2: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.

F4: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.

F5: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV.

F6: The shares are held by VV IV.

F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.

F8: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F10: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.

F11: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").

F12: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.

F13: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").

F14: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.

F15: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN").

F16: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.

Tempest Therapeutics, Inc.

Report date August 08, 2024 · Filed August 12, 2024

Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	209,941	Last balance in matching sequence After 2024-08-12 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2024-08-08 · Sale · Disposed 400,000 · Balance 597,940 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 2 · 2024-08-12 · Sale · Disposed 387,999 · Balance 209,941 F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,171,094	Reported balance Holding disclosure · report date 2024-08-08 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,171,094 F4: These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV and may be deemed to share voting, investment and dispositive power over the shares held by VVC IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,377	Reported balance Holding disclosure · report date 2024-08-08 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 7,377 F5: These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV and may be deemed to share voting, investment and dispositive power over the shares held by VSF IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,118,644	Reported balance Holding disclosure · report date 2024-08-08 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 2,118,644 F6: These shares are held of record by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP and each may be deemed to share voting, investment and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP and Vantage II GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4: These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV and may be deemed to share voting, investment and dispositive power over the shares held by VVC IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.

F5: These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV and may be deemed to share voting, investment and dispositive power over the shares held by VSF IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.

F6: These shares are held of record by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP and each may be deemed to share voting, investment and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP and Vantage II GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Contineum Therapeutics, Inc.

Report date April 09, 2024 · Filed April 11, 2024

Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP, L.P., Versant Vantage I GP-GP, LLC, Versant Venture Capital IV, L.P., Versant Ventures IV, LLC

Section 16 reporting ended · disclosed 2024-04-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	391,785	Reported balance After 2024-04-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-09 · Conversion · Acquired 391,785 · Balance 391,785 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	2,531	Reported balance After 2024-04-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-09 · Conversion · Acquired 2,531 · Balance 2,531 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	148,312	Reported balance After 2024-04-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-09 · Conversion · Acquired 148,312 · Balance 148,312 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-04-09 · Conversion · Acquired 298,975 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-04-09 · Conversion · Acquired 1,931 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	1,476,446	Reported balance After 2024-04-09 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-04-09 · Conversion · Acquired 1,476,446 · Balance 1,476,446 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	9,252	Reported balance After 2024-04-09 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2024-04-09 · Conversion · Acquired 9,252 · Balance 9,252 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-04-09 · Conversion · Acquired 70,498 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-04-09 · Conversion · Acquired 455 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-04-09 · Conversion · Acquired 90,747 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	1,824,589	Reported balance After 2024-04-09 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2024-04-09 · Conversion · Acquired 348,143 · Balance 1,824,589 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	11,434	Reported balance After 2024-04-09 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2024-04-09 · Conversion · Acquired 2,182 · Balance 11,434 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	434,725	Reported balance After 2024-04-09 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2024-04-09 · Conversion · Acquired 434,725 · Balance 434,725 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-04-09 · Conversion · Acquired 22,312 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-04-09 · Conversion · Acquired 145 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2024-04-09 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-04-09 · Conversion · Acquired 57,565 · Balance 0 F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	1,934,776	Reported balance After 2024-04-09 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2024-04-09 · Conversion · Acquired 110,187 · Balance 1,934,776 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	12,123	Reported balance After 2024-04-09 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2024-04-09 · Conversion · Acquired 689 · Balance 12,123 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	710,494	Reported balance After 2024-04-09 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2024-04-09 · Conversion · Acquired 275,769 · Balance 710,494 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	1,423,119	Reported balance After 2024-04-09 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2024-04-09 · Conversion · Acquired 1,423,119 · Balance 1,423,119 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F5: The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	1,741,107	Reported balance After 2024-04-09 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2024-04-09 · Conversion · Acquired 317,988 · Balance 1,741,107 F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date. F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer. F5: The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	Direct	375,535	Reported balance Holding disclosure · report date 2024-04-09 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 375,535 F5: The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date.

F2: The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.

F3: The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.

F4: The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.

F5: The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

F6: In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date.

F7: Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer.

IVERIC bio, Inc.

Report date June 19, 2020 · Filed June 23, 2020

Jointly reported with Versant Venture Capital IV, L.P., Versant Ventures IV, LLC

Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectfootnote	1,714,111	Reported balance After 2020-06-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-06-19 · Other · Disposed 3,428,221 · Balance 1,714,111 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2: These shares are held by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV may be deemed to indirectly beneficially own the shares beneficially owned by VVC IV, but disclaims beneficial ownership except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	Indirectfootnote	10,798	Reported balance After 2020-06-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-06-19 · Other · Disposed 21,597 · Balance 10,798 F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4: These shares are held by VSF IV. VV IV is the sole general partner of VSF IV may be deemed to indirectly beneficially own the shares beneficially owned by VSF IV, but disclaims beneficial ownership except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	Indirectfootnote	34,282	Reported balance After 2020-06-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-06-19 · Other · Acquired 34,282 · Balance 34,282 F5: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6: The shares are held by VV IV.
Common StockSEC Table I · non-derivative	Indirectfootnote	0	Reported balance After 2020-06-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2020-06-19 · Other · Disposed 34,282 · Balance 0 F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6: The shares are held by VV IV.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.

F2: These shares are held by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV may be deemed to indirectly beneficially own the shares beneficially owned by VVC IV, but disclaims beneficial ownership except to the extent of its pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.

F4: These shares are held by VSF IV. VV IV is the sole general partner of VSF IV may be deemed to indirectly beneficially own the shares beneficially owned by VSF IV, but disclaims beneficial ownership except to the extent of its pecuniary interest therein.

F6: The shares are held by VV IV.

F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.

Inari Medical, Inc.

Report date November 17, 2020 · Filed November 19, 2020

Jointly reported with Versant Ventures IV, LLC, Versant Venture Capital IV, L.P.

Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,705,162	Reported balance After 2020-11-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-17 · Other · Disposed 3,004,415 · Balance 2,705,162 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("Versant IV"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F2: Shares held by Versant IV. Versant Ventures IV, LLC ("Versant Ventures IV GP") is the general partner of Versant IV. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee footnote	164,825	Reported balance After 2020-11-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-11-17 · Other · Acquired 164,825 · Balance 164,825 F3: Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV. F4: Shares held by Versant Ventures IV GP. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-11-17 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-11-17 · Other · Disposed 164,825 · Balance 0 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members. F4: Shares held by Versant Ventures IV GP. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee footnote	17,040	Reported balance After 2020-11-17 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2020-11-17 · Other · Disposed 18,925 · Balance 17,040 F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("Versant Side Fund"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F7: Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("Versant IV"), to its partners, pursuant to a Rule 10b5-1 distribution plan.

F2: Shares held by Versant IV. Versant Ventures IV, LLC ("Versant Ventures IV GP") is the general partner of Versant IV. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.

F3: Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV.

F4: Shares held by Versant Ventures IV GP. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.

F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members.

F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("Versant Side Fund"), to its partners, pursuant to a Rule 10b5-1 distribution plan.

F7: Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. Kirk G. Nielsen is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Kirk G. Nielsen is a director of the Issuer and, accordingly, files separate Section 16 reports.

Oyster Point Pharma, Inc.

Report date January 03, 2023 · Filed January 04, 2023

Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-01-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-01-03 · Other · Disposed 2,236,888 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F3: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and Clare Ozawa disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	Reported balance After 2023-01-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-01-03 · Other · Disposed 414,607 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F4: Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of Versant IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant IV, except to the extent of its pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	Reported balance After 2023-01-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2023-01-03 · Other · Disposed 2,465 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F5: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). Versant Ventures IV is the sole general partner of Versant Side Fund IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of its pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	Reported balance After 2023-01-03 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2023-01-03 · Other · Disposed 1,003,658 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F6: Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and Clare Ozawa disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)

F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

F3: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and Clare Ozawa disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.

F4: Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of Versant IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant IV, except to the extent of its pecuniary interests therein.

F5: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). Versant Ventures IV is the sole general partner of Versant Side Fund IV. Versant Ventures IV disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of its pecuniary interests therein.

F6: Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and Clare Ozawa disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 24, 2016 Filed Oct 26, 2016 22:28 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantCommon Stock	60,219	$14.00	$843,066.00	Disclosure SEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,443,803 F3 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 26, 2016 22:28 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantCommon Stock	602	$14.00	$8,428.00	Disclosure SEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,334 F2 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 26, 2016 22:28 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantCommon Stock	95,596	$14.00	$1,338,344.00	Disclosure SEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,104,045 F1 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	5,774	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 32 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	13,180	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 31 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	5,210	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 30 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	173,167	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 29 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 173,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	1,454	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 28 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	231,077	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 27 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 231,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-3 Preferred Shares · Derivative	73,704	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 26 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 73,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-3 Preferred Shares · Derivative	168,224	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 25 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 168,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-3 Preferred Shares · Derivative	66,490	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 24 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 66,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-3 Preferred Shares · Derivative	2,210,417	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 23 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,210,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-2 Preferred Shares · Derivative	19,524	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 22 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-2 Preferred Shares · Derivative	3,100,477	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 21 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,100,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-1 Preferred Shares · Derivative	2,754	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 20 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries A-1 Preferred Shares · Derivative	437,247	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 19 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 437,247 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	5,774	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 18 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 79,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	73,704	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 17 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 73,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	4,583	$14.00	$64,162.00	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 16 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 185,987 F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	13,180	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 15 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 181,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	168,224	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 14 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 168,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	5,210	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 13 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 71,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	66,490	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 12 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 66,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	60,219	$14.00	$843,066.00	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 11 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,443,803 F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	173,167	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 10 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,383,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	2,210,417	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 9 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,210,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	602	$14.00	$8,428.00	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 8 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 24,334 F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	1,454	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 7 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 23,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	19,524	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 6 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 22,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	2,754	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 5 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	95,596	$14.00	$1,338,344.00	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,104,045 F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	231,077	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,008,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	3,100,477	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 3,777,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document
October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	437,247	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 676,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.